Summary
4.67
0.19
(4.24%)
06/12/2026
Exagen Inc. (XGN)Key Facts
Performance
Historical returns1D
4.24%
1W
11.19%
1M
25.88%
3M
47.78%
6M
-34.32%
1Y
-33.09%
5Y
-72.45%
Snapshot
Key statisticsClose
4.67
Change
0.19
Change %
4.24%
Open
4.46
Day Range
4.46 – 4.70
Volume
145,515
Avg Vol (20d)
408,906
Rel Vol
0.36x
52W Range
2.59 - 12.23
vs 52W High
-61.82%
vs 52W Low
80.31%
Gap
-0.03
Market Cap
USD 216.41M
Beta
1.66
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
Financial SnapshotFY 2025
Full financialsRevenue
USD 66.58M
+19.7% YoY
Net Income
-USD 19.95M
+32.0% YoY
EPS
-0.93
+12.0% YoY
Gross Margin
58.3%
Operating Margin
-21.1%
Net Margin
-30.0%
EBITDA
-USD 11.95M
Free Cash Flow
-USD 14.27M
-21.4% margin
ROE
-114.3%
ROA
-34.4%
Debt / Equity
0.31x
net debt -USD 26.82M
Cash & Equiv.
USD 32.22M
Fundamental Ratings
MainC-
RecommendedStrong Sell
DCFStrong Sell
ROEStrong Sell
ROAStrong Sell
Debt/EquitySell
P/EStrong Sell
P/BSell
Latest Earnings
- XGN reported last earnings on 2026-05-11.
- EPS of $-0.17 vs $-0.24 estimated — surprise $0.07.
- Revenue of $17M vs $16M estimated — surprise $1M.
News
All newsExagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical...
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Q1 Earnings Call Highlights
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. Reports First Quarter 2026 Results
CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.
Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $1.81 per share a year ago.
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026.
Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of “Moderate Buy” by Analysts
Exagen Inc. (NASDAQ: XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average...
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Q4 2025 Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.2 per share a year ago.
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results
Record full-year total revenue and AVISE® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today reported...
Exagen Inc. (NASDAQ:XGN) Receives Average Rating of “Moderate Buy” from Analysts
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The...
Exagen Inc. to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences: KeyBank Capital Markets Healthcare Forum - Virtual Date: March 17, 2026 Participation:...
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025, before the market opens on Tuesday, March 10, 2026. John Aballi, President and Chief Executive...
Exagen Inc. Announces Select Preliminary 2025 Financial Results
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
Exagen Inc. (NASDAQ:XGN) Given Consensus Rating of “Moderate Buy” by Analysts
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the...
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences:
Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript
Exagen Inc. ( XGN ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Ryan Douglas - Investors Relations Officer John Aballi - CEO, President & Director Jeffrey Black - CFO & Corporate Secretary Conference Call Participants Anderson Schock - B. Riley Securities, Inc., Research...
Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.28 per share a year ago.